Welcome to our dedicated page for Cyclo Therapeutics news (Ticker: CYTH), a resource for investors and traders seeking the latest updates and insights on Cyclo Therapeutics stock.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH) is a clinical-stage biotechnology company whose news flow centers on the development of its lead investigational product, Trappsol® Cyclo™, for Niemann-Pick Disease Type C1 (NPC1) and early Alzheimer’s disease. News updates commonly highlight progress in the pivotal Phase 3 TransportNPC™ trial, data from clinical sub-studies, and regulatory and intellectual property milestones.
Investors and followers of CYTH can expect clinical trial updates, including completion of enrollment milestones, interim analyses plans, and preliminary safety and efficacy findings from the TransportNPC™ study and its open-label sub-study in very young NPC1 patients. The company frequently reports on presentations at major scientific meetings such as WORLDSymposium™ and the SSIEM Annual Symposium, where it shares poster and oral presentation data on long-term treatment, safety profiles and clinical outcomes.
Cyclo Therapeutics’ news also covers regulatory strategy developments, such as alignment with the U.S. Food and Drug Administration and European Medicines Agency on potential NDA and MAA submissions based on interim Phase 3 data, as well as the impact of Orphan Drug, Fast Track and Rare Pediatric Disease designations. In addition, the company issues updates on its Alzheimer’s disease program, including patent grants in the U.S. and Europe for methods of treating Alzheimer’s disease with Trappsol® Cyclo™ and progress in its Phase 2b trial.
Corporate and financial announcements, including quarterly and annual results, merger activity with entities such as Applied Molecular Transport and agreements with Rafael Holdings, Inc., are also part of the CYTH news stream. Readers who track CYTH news gain insight into the company’s clinical progress, regulatory path, scientific visibility and financing strategy as it advances Trappsol® Cyclo™ in rare disease and neurodegenerative indications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Cyclo Therapeutics (Nasdaq: CYTH) announced the closing of a private placement of its securities, raising approximately $1.3 million from accredited investors, including directors and management. The company sold 1,562,883 shares of common stock at a price of $0.84 each, accompanied by warrants for an equal number of shares with a $0.71 exercise price, valid for seven years. The funds will be directed towards working capital and general corporate purposes, supporting its Trappsol® Cyclo™ development programs for rare diseases such as Niemann-Pick Disease Type C. The private placement was conducted under Regulation D and relevant exemptions from the Securities Act of 1933, meaning that the securities cannot be sold in the U.S. without effective registration or applicable exemptions.
Cyclo Therapeutics (NASDAQ: CYTH) reports significant progress in its clinical programs for Trappsol® Cyclo™. The pivotal Phase 3 TransportNPC™ study for Niemann-Pick Disease Type C1 has achieved 40% enrollment and is expected to complete by year-end 2023. The company is also advancing a Phase 2b study for early Alzheimer’s Disease, with patient dosing ongoing. In January 2023, Cyclo Therapeutics completed financing, raising net proceeds of $3.7 million. The company's financial results for 2022 included a net loss of $15.5 million, while research expenses decreased slightly. Cyclo Therapeutics maintained a cash position of approximately $1.5 million as of year-end.
Cyclo Therapeutics (NASDAQ: CYTH) announced significant progress in its clinical programs for Trappsol® Cyclo™. The pivotal Phase 3 study, TransportNPC™, is on track with 35% enrollment completed, expecting full enrollment by year-end 2023. Additionally, patient enrollment for a Phase 2b study in early Alzheimer’s Disease is underway. CEO N. Scott Fine emphasized the company's commitment to addressing unmet medical needs in Niemann-Pick Disease Type C and Alzheimer's Disease. Key achievements in 2022 were also highlighted, reaffirming the company's focus and resource allocation to these critical areas.
Cyclo Therapeutics, Inc. (NASDAQ: CYTH), a clinical-stage biotechnology company, will be presenting at the Virtual Investor 2023 Companies to Watch Event on January 19, 2023, at 11:00 AM ET. CEO N. Scott Fine will lead the presentation, which will be accessible through a live video webcast. Cyclo Therapeutics focuses on developing treatments for diseases, particularly with its orphan drug Trappsol® Cyclo™ aimed at Niemann-Pick Disease Type C and early Alzheimer’s disease.